PMP22 and Charcot-Marie-Tooth disease type 2A1: Using 3D cultures of cells derived from patients with Charcot–Marie–Tooth disease (CMT2A), a recent study generated organoids containing myelinating Schwann cells, enabling the testing of PMP22 inhibitors and the study of cell interactions in peripheral neuropathies (Van Lent et al., 2023).